Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Nov;135(5):931-7.

Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma

Affiliations

Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma

D Jordon et al. Am J Pathol. 1989 Nov.

Abstract

Despite major advances in the differential diagnosis of mesotheliomas versus adenocarcinomas, a certain percentage defy diagnosis. Several markers such as keratin, carcinoembryonic antigen, Leu-M1, milk fat globulin, and antibody against tumor-associated glycoprotein Tag-72 (B72.3) have been used to distinguish them. In this study, blood group antigens, namely Lewisx and Lewisy, known to be expressed in a number of adenocarcinomas of diverse origin were used in the differential diagnosis of 30 samples from 18 mesotheliomas and 18 primary lung adenocarcinomas. Adenocarcinomas showed strong diffuse homogeneous staining, membranous staining, or both for Lewisy in 100% of cases irrespective of differentiation. Lewisx was expressed in 78% of adenocarcinomas with a wide variation in distribution of staining. Mesotheliomas did not show the diffuse homogeneous staining pattern but showed a markedly distinctive granular staining in the cytoplasm of rare cells in 23% of Lewisy and 20% of Lewisx cases, which was interpreted as negative. In conclusion, Lewisy is a sensitive marker for adenocarcinomas in that it stains 100% of cases and is a specific marker in the differential diagnosis of mesotheliomas and adenocarcinomas.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Urol. 1975 Dec;114(6):874-8 - PubMed
    1. Acta Cytol. 1989 Jul-Aug;33(4):499-504 - PubMed
    1. Am J Pathol. 1982 Jul;108(1):80-8 - PubMed
    1. Hum Pathol. 1983 Jan;14(1):70-6 - PubMed
    1. Am J Surg Pathol. 1984 Apr;8(4):277-9 - PubMed

Substances

LinkOut - more resources